ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "innate immunity"

  • Abstract Number: 1001 • ACR Convergence 2021

    Exosomes Mediate a Cooperative Mechanism of Macrophage/Fibroblast Activation in Systemic Sclerosis

    Rajan Bhandari1, Heetaek Yang2, Noelle Kosarek3, Michael Whitfield4 and Patricia Pioli1, 1Geisel School of Medicine at Dartmouth, Lebanon, NH, 2Geisel School of Medicine, Hanover, NH, 3Dartmouth Geisel School of Medicine, Hartford, VT, 4Geisel School of Medicine, Lebanon, NH

    Background/Purpose: Prior work demonstrates that macrophages (MØs) from patients with Systemic Sclerosis (SSc) produce fibrotic and pro-inflammatory mediators and that cocultured MØs and SSc fibroblasts…
  • Abstract Number: 1455 • ACR Convergence 2020

    Functional Characterization of PLCG2 Mutations Found in Subjects with Autoinflammation and PLCG2-Associated Antibody Deficiency and Immune Dysregulation (APLAID) Reveals Both Hypermorphic and Hypomorphic Mutants

    Kathleen Baysac1, Charles Fisher2, Hiroto Nakano2, Joshua Milner3 and Michael Ombrello4, 1NIAMS, NIH, Bethesda, MD, 2NIAMS, NIH, Bethesda, 3Division of Allergy, Immunology and Rheumatology Columbia University Medical Center, New York, NY, 4Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD

    Background/Purpose: PLCG2-associated antibody deficiency and immune dysregulation (PLAID) and autoinflammatory PLAID (APLAID) are autosomal dominant diseases caused by mutations of PLCG2. APLAID is clinically characterized by episodic…
  • Abstract Number: 0062 • ACR Convergence 2020

    The Role of PGLYRP1 in the Pathogenesis of Lyme Disease

    Akash Gupta1, Gunjan Arora1, Connor Rosen2, Yongguo Cao1, Jiri Cerny3, Carmen Booth4, Noah Palm2, Aaron Ring2 and Erol Fikrig1, 1Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 2Department of Immunobiology, Yale University School of Medicine, New Haven, CT, 3Faculty of Tropical AgriSciences, Czech University of Life Sciences in Prague, Prague, Czech Republic, 4Department of Comparative Medicine, Yale University School of Medicine, New Haven, CT

    Background/Purpose: Lyme Disease is caused by the spirochete Borrelia Burgdorferi (Bb). The infection often begins in the skin, following a tick bite, and spreads to…
  • Abstract Number: 1517 • ACR Convergence 2020

    Metabolic Regulation of Type 3 Innate Lymphoid Cells by Intestinal Bacteria-Derived Indoles in Ankylosing Spondylitis

    Adam Berlinberg1, Adam Lefferts2, Emilie Regner3, Andrew Stahly4 and Kristine Kuhn4, 1University of Colorado, Denver, CO, 2University of Colorado, Anschutz Medical Campus, Denver, CO, 3University of California San Francisco, San Francisco, CA, 4University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Intestinal microbial dysbiosis, intestinal inflammation, and Th17 immunity are all linked to the pathophysiology of ankylosing spondylitis (AS); however, the mechanisms linking them remain…
  • Abstract Number: 0063 • ACR Convergence 2020

    Novel Repurposed Drugs Against Joint Inflammation Reveal Potential Use for Gout Treatment: An In Silico, In Vitro and Clinical Study

    Eloi Franco-Trepat1, Ana Alonso-Pérez1, Maria Guillán-Fresco1, Miriam López-Fagundez1, Andrés Pazos-Pérez1, Ana Lois Iglesias2, Susana Belén Bravo3, Alberto Jorge-Mora1, JJ Gómez-Reino4 and Rodolfo Gómez1, 1IDIS-CHUS - Musculoskeletal Pathology Group, Santiago de Compostela, Spain, 2IDIS-CHUS - Musculoskeletal Pathology Group, A Coruna, Spain, 3IDIS-CHUS - Proteomics Unit, Santiago de Compostela, Galicia, Spain, 4IDIS-CHUS - Rheumatology Group, Santiago de Compostela, Spain

    Background/Purpose: Joint inflammation is a common feature across multiple rheumatic diseases. To deal with the induction of innate immune factors, targeting therapeutic targets such as…
  • Abstract Number: 1531 • ACR Convergence 2020

    Characterization of Cytokine/chemokine Profile in Patient-derived M1/ M2 Macrophages to Identify Biomarkers for Genetically-defined Systemic Autoinflammatory Diseases

    Farzana Bhuyan1, Adriana Almeida de Jesus2, Kim Johnson3, Jacob Mitchell4, Yan Huang5 and Raphaela Goldbach-Mansky5, 1NIH, bhetesda, MD, 2Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, 3NIH, NIAID, Bethesda, 4Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 5NIH, Bethesda

    Background/Purpose: Genetic mutations in key regulatory molecules of the innate immune system cause autoinflammatory diseases through propagation of hyperinflammatory responses. Monocytes/ macrophages regulate inflammatory processes…
  • Abstract Number: 0064 • ACR Convergence 2020

    Neutrophil Extracellular Traps Are Sufficient to Activate the Alternative Pathway of Complement

    Rebecca Schriefer1, Michelle Elvington2, Priyan Weerappuli3 and Alfred Kim4, 1Washington University School of Medicine, Saint Louis, MO, 2Kypha, Inc., Saint Louis, MO, 3University of Michigan, Ann Arbor, MI, 4Washington University School of Medicine, St. Louis, MO

    Background/Purpose: Systemic lupus erythematosus (SLE) replies on complement activation to drive many of the pathophysiologic features of disease. We and others have noted that SLE…
  • Abstract Number: 1636 • ACR Convergence 2020

    8 Years Follow-Up of a Novel Autoinflammatory Disease: CD59 Malfunction Causes Hemolytic Anemia, Recurrent Guillain-Barre Syndrome, and Strokes in Pediatric Populations and Respond Well to Eculizumab and Pozelimab

    Dror Mevorach1 and Netanel Karbian1, 1Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel

    Background/Purpose: In 2013 we have described the first patients with a novel autoinflammatory disease manifested in 4 children with recurrent Guillain-Barre syndrome and hemolytic anemia…
  • Abstract Number: 0074 • ACR Convergence 2020

    The Intracellular DNA Sensor STING Protects Against Bone Loss Through Regulation of Type I Interferons

    Susan MacLauchlan1, Catherine Manning2, Sijia Chen3, Katherine Fitzgerald4, Shruti Sharma5 and Ellen Gravallese1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women’s Hospital, Boston, 3Brigham and Women's Hospital, Boston, 4University of Massachusetts medical school, Worcester, MA, 5Tufts University, Boston, MA

    Background/Purpose: The intracellular DNA sensor Stimulator of Interferon Genes (STING) is essential for detection of viral and bacterial pathogen DNA. As with other pathways in…
  • Abstract Number: 1810 • ACR Convergence 2020

    Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine

    Anne Margrethe Troldborg1, Annette Hansen2, Kristian Stengaard-Pedersen2 and Steffen Thiel2, 1Aarhus University Hospital, Arhus, Denmark, 2Aarhus University, Aarhus, Denmark

    Background/Purpose: Mortality in patients with systemic lupus erythematosus (SLE) is significantly higher than in the general population. Treatment of SLE patients has improved, however, a…
  • Abstract Number: 0176 • ACR Convergence 2020

    Characterization and Molecular Mechanism Underlying NEMO Deleted Exon 5 Autoinflammatory Syndrome (NDAS)

    Alex Wessel1, Younglang Lee2, Eries Lee3, Jiazhi Xu4, Somin Kim5, Amy Hsu6, Jevgenia Rudenko7, Clinton Enos8, Stephen Brooks3, Zuoming Deng9, Bin Lin10, Daniel Hupalo11, Adriana Almeida de Jesus12, Daniela Piotto13, Maria Teresa Terreri14, Victoria Dimitriades15, Dalgard Clifton11, Steven Holland16, Raphaela Goldbach-Mansky17, Richard Siegel18 and Eric Hanson19, 1Washington University St. Louis, St. Louis, 2PUsan National University, Pusan, Republic of Korea, 3NIAMS, NIH, Bethesda, 4Indiana University School of Medicine, Indianapolis, 5Emory University, Atlanta, 6NIAID, NIH, Bethesda, 7OHSU, Portland, 8Eastern Virginia Medical School, Norfolk, 9National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, 10Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 116The American Genome Center, Collaborative Health Initiative Research Program, Uniformed Services University of the Health Sciences, Bethesda, 12Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, 137Escola Paulista de Medicina/Universidade Federal de São Paulo, Sao Paolo, Brazil, 14Federal University of São Paulo, São Paulo, Brazil, 15Division of Infectious Diseases, Immunology & Allergy University of California Davis Health, Sacramento, 16Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases, Bethesda, 17NIH, Bethesda, 18Novartis Institutes for BioMedical Research, Basel, Switzerland, 19Riley Hospital for Children, IUSM, Indianapolis, IN

    Background/Purpose: The NF-kB essential modulator (NEMO) is a scaffolding protein with a broad immune cell and tissue expression profile. Hypomorphic mutations in IKBKG encoding NEMO…
  • Abstract Number: 1861 • ACR Convergence 2020

    T Cells with IL-17A+ Signature in Psoriatic Arthritis Are of Different Subpopulations and Are Polyfuntional

    Siba Raychaudhuri1 and Smriti Raychaudhuri2, 1Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, 2VA Sacramento Medical Center, Davis, CA

    Background/Purpose: A variety of T cells such as Th1, Th2, Th9, Th17, NKT, MAIT, etc have been attributed to multiple autoimmune diseases.  In psoriatic arthritis…
  • Abstract Number: 0282 • ACR Convergence 2020

    Expression of the cGAMP Transporter SLC19A1 Is Altered in Systemic Lupus Erythematosus

    Jeong Min Yu1, Gantsetseg Tumurkhuu2, Erica Montano2, Gabriela de los Santos2, Daniel J Wallace2, Mariko Ishimori3 and Caroline Jefferies1, 1Cedars-Sinai Medical Center, West Hollywood, CA, 2Cedars-Sinai Medical Center, Los Angeles, 3Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Inappropriate sensing of nucleic acids leading to enhanced type I interferon (IFN) induction is a hallmark of SLE, contributing to breakdown of immune tolerance…
  • Abstract Number: 1953 • ACR Convergence 2020

    Somatic Mutations in a Single Residue of UBA1 Cause VEXAS, a Severe Adult-Onset Rheumatic Disease Presenting as Relapsing Polychondritis, Polyarteritis Nodosa, or Giant Cell Arteritis

    David Beck1, Marcela Ferrada2, Keith Sikora3, Amanda Ombrello4, Daniela Ospina Cardona5, Nicholas Balanda6, Wuhong Pei6, Jason Collins6, Robert Colbert7, Mariana Kaplan8, Massimo Gadina9, Sinisa Savic10, Helen Lachmann11, Kyle Retterer12, Shawn Burgess13, William Gahl6, Achim Werner6, Ivona Aksentijevich14, Neal S. Young6, Katherine R. Calvo6, Peter C. Grayson15 and Daniel Kastner16, 1National Human Genome Research Institute, Bethesda, 2Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3National Institutes of Health Clinical Center, Bethesda, MD, 4National Human Genome Research Institute/National Institutes of Health, Bethesda, MD, 5National Institute of Health, Bethesda, 6National Institutes of Health, Bethesda, 7Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, 8National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 9National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, 10University of Leeds, England, United Kingdom, 11National Amyloidosis CenterRoyal Free Campus, Rowland Hill St, London, United Kingdom, 12GeneDX, Gaithersburg, 13National Institutes of Health, Bethesda, MD, 14National Human Genome Research Institute, Bethesda, MD, 15Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, 16National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD

    Background/Purpose: Identifying the causes of adult-onset rheumatic diseases remains a challenge, and limits diagnosis, prognosis, and targeted treatment. We hypothesized that mutations in genes regulating…
  • Abstract Number: 0287 • ACR Convergence 2020

    RNA Externalized by Neutrophil Extracellular Traps Promotes Inflammatory Pathways in Endothelial Cells

    Xinghao Wang1, Philip Carlucci2, Jorge Romo-Tena1, Jose Torres-Ruiz1, Hong-Wei Sun1, Markus Hafner1, Mariana Kaplan3 and Luz Blanco4, 1NIAMS, National Institute of Health, Bethesda, 2New York University School of Medicine, New York, NY, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville

    Background/Purpose: Neutrophil extracellular traps (NETs) are extracellular lattices composed of nucleic material bound to neutrophil granule proteins. NETs may play pathogenic roles in development and…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology